IT SUPPRESSES ENDOGENOUS CHOLESTEROL SYNTHESIS, CAUSING THE EXPRESSION OF AN INCREASED NUMBER OF SPECIFIC LDL (LOW DENSITY LIPOPROTEINS) RECEPTORS AND THUS AN INCREASED CATABOLISM OF LDL WHICH LEADS TO LOWER PLASMA CHOLESTEROL. IT ALSO SUPPRESSES THE ENDOGENOUS SYNTHESIS OF TRIGLYCERIDES WHILE SIMULTANEOUSLY STIMULATING THEIR CATABOLISM THROUGH SYSTEMIC LIPOPROTEIN LIPASE AND HEPATIC LIPASE. FENOFIBRIC ACID, THE ACTIVE METABOLITE OF FENOFIBRATE, PRODUCES REDUCTIONS IN TOTAL CHOLESTEROL, LDL CHOLESTEROL, APOLIPOPROTEIN B, TOTAL TRIGLYCERIDES AND TRIGLYCERIDE RICH LIPOPROTEIN (VLDL) IN TREATED PATIENTS. IN ADDITION, TREATMENT WITH FENOFIBRATE RESULTS IN INCREASES IN HIGH DENSITY LIPOPROTEIN (HDL) AND APOPROTEINS APOAI AND APOAII.